PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market segmentation analysis • Market characteristics PART 04: PIPELINE ANALYSIS • Pipeline analysis PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Injections - Market size and forecast 2018-2023 • Topicals - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie • Bayer • Endo Pharmaceuticals PART 14: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global endocrinology drugs market Exhibit 03: Segments of global endocrinology drugs market Exhibit 04: Market segments Exhibit 05: Market characteristics Exhibit 06: Late-stage pipeline analysis drugs for testosterone deficiency Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Injections - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Injections - Year-over-year growth 2019-2023 (%) Exhibit 23: Topicals - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Topicals - Year-over-year growth 2019-2023 (%) Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Others - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by product Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Americas - Year-over-year growth 2019-2023 (%) Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 36: APAC - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Decision framework Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: AbbVie - Vendor overview Exhibit 47: AbbVie - Business segments Exhibit 48: AbbVie - Organizational developments Exhibit 49: AbbVie - Geographic focus Exhibit 50: AbbVie - Key offerings Exhibit 51: Bayer - Vendor overview Exhibit 52: Bayer - Business segments Exhibit 53: Bayer - Organizational developments Exhibit 54: Bayer - Geographic focus Exhibit 55: Bayer - Segment focus Exhibit 56: Bayer - Key offerings Exhibit 57: Endo Pharmaceuticals - Vendor overview Exhibit 58: Endo Pharmaceuticals - Business segments Exhibit 59: Endo Pharmaceuticals - Organizational developments Exhibit 60: Endo Pharmaceuticals - Geographic focus Exhibit 61: Endo Pharmaceuticals - Segment focus Exhibit 62: Endo Pharmaceuticals - Key offerings Exhibit 63: Validation techniques employed for market sizing Exhibit 64: List of abbreviations  

AbbVie Bayer Endo Pharmaceuticals